<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="combination with other antiviral or non-antiviral drugs in patients with" exact="hepatitis" post="B and hepatic fibrosis. Objectives: The current randomized controlled"/>
 <result pre="indexes of liver function and liver fibrosis in patients with" exact="hepatitis" post="B. Data Sources: Published literatures in Chinese and English"/>
 <result pre="in Chinese and English on hepatoprotective treatment strategies for chronic" exact="hepatitis" post="B and liver fibrosis were searched in three databases"/>
 <result pre="improve liver function and liver fibrosis parameters in patients with" exact="hepatitis" post="B. Hepatitis B Liver Cirrhosis Meta-Analysis Ursodeoxycholic Acid (UDCA)"/>
 <result pre="Hepatitis B can lead to serious liver diseases, including cirrhosis," exact="liver cancer." post="In China, approximately 120 million people are infected with"/>
 <result pre="in Iran, and 15% to 40% of the patients with" exact="hepatitis" post="B may develop cirrhosis or liver cancer (2). Liver"/>
 <result pre="to 40% of the patients with hepatitis B may develop" exact="cirrhosis" post="or liver cancer (2). Liver fibrosis is a healing"/>
 <result pre="of the patients with hepatitis B may develop cirrhosis or" exact="liver cancer" post="(2). Liver fibrosis is a healing response, but the"/>
 <result pre="the patients with hepatitis B may develop cirrhosis or liver" exact="cancer" post="(2). Liver fibrosis is a healing response, but the"/>
 <result pre="often leads to severe forms of liver fibrosis, and ultimately" exact="cirrhosis" post="with liver dysfunction (3-5). Early cirrhosis may be reversible."/>
 <result pre="liver fibrosis, and ultimately cirrhosis with liver dysfunction (3-5). Early" exact="cirrhosis" post="may be reversible. Therefore, prompt diagnosis and intervention are"/>
 <result pre="acid, and improves cholestasis. UDCA is mainly used to treat" exact="primary biliary cirrhosis," post="hepatitis B associated liver fibrosis, and cholestatic liver disease,"/>
 <result pre="cholestasis. UDCA is mainly used to treat primary biliary cirrhosis," exact="hepatitis" post="B associated liver fibrosis, and cholestatic liver disease, the"/>
 <result pre="primary biliary cirrhosis, hepatitis B associated liver fibrosis, and cholestatic" exact="liver disease," post="the efficacy is certain. Some studies reported that UDCA"/>
 <result pre="the United States and Europe, about 65% of patients with" exact="liver disease" post="use Chinese medical preparations which include milk thistle as"/>
 <result pre="used to treat liver cirrhosis, hepatitis, liver fibrosis and alcoholic" exact="liver disease" post="(15). N-acetylcysteine (NAC) is an intracellular glutathione precursor, which"/>
 <result pre="caused by excessive acetaminophen (paracetamol), but is also useful for" exact="liver disease" post="arising from other causes (18). NAC reduces serum Total"/>
 <result pre="and increases Prothrombin activity (PTA) in patients with severe chronic" exact="hepatitis" post="B (19). 2. Objectives The current study aimed to"/>
 <result pre="indexes of liver function and liver fibrosis in patients with" exact="hepatitis" post="B. 3. Data Sources Papers written in either English"/>
 <result pre="or Chinese describing the use of hepatoprotective agents to treat" exact="hepatitis" post="and liver fibrosis were retrieved. Using &quot;chronic hepatitis B,"/>
 <result pre="to treat hepatitis and liver fibrosis were retrieved. Using &quot;chronic" exact="hepatitis" post="B, hepatitis B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin,"/>
 <result pre="hepatitis and liver fibrosis were retrieved. Using &quot;chronic hepatitis B," exact="hepatitis" post="B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin, silybin meglumine),"/>
 <result pre="4.1.1. Inclusion Criteria Hepatitis B infection or liver fibrosis; chronic" exact="hepatitis" post="B was diagnosed if HBV history or HBV markers"/>
 <result pre="Studies in which non-protective liver drugs were used to treat" exact="viral hepatitis" post="or liver fibrosis; animal experiments and reviewed papers that"/>
 <result pre="in which non-protective liver drugs were used to treat viral" exact="hepatitis" post="or liver fibrosis; animal experiments and reviewed papers that"/>
 <result pre="not contain clinical data; pregnant and lactating female patients with" exact="liver disease." post="The therapy course was less than three weeks; liver"/>
 <result pre="drug in combination with an antiviral agent treatment of chronic" exact="hepatitis" post="B. The test and control groups included 741 and"/>
 <result pre="ALT, AST, ALP and TBIL Levels In patients with chronic" exact="hepatitis" post="B infection treated with combination hepatoprotective and antiviral drug"/>
 <result pre="with placebo on liver function indexes in patients with chronic" exact="hepatitis" post="B, including ALT and TBIL. In these trials, the"/>
 <result pre="three hepatoprotective agents significantly decreased ALT levels in patients with" exact="hepatitis" post="B. NAC was associated with greater efficacy compared to"/>
 <result pre="of UDCA and silibinin on ALT levels in patients with" exact="hepatitis" post="B were considerable: NAC (WMD = -25.66; P ="/>
 <result pre="Plots Indicating Reduced Amounts of ALT In patients with chronic" exact="hepatitis" post="B infection treated with hepatoprotective drugs vs. placebo. Data"/>
 <result pre="over NAC and silibinin to reduce TBIL in patients with" exact="hepatitis" post="B. Meta-analysis showed that NAC (WMD = -2.56; P"/>
 <result pre="Agents vs. Placebo on TBIL Levels In patients with chronic" exact="hepatitis" post="B infection. Data are presented as pooled relative risks"/>
 <result pre="agents compared to only one to treat patients with chronic" exact="hepatitis" post="B. There were 618 subjects in the two hepatoprotective"/>
 <result pre="ALT, AST, GGT, ALP and TBIL levels in patients with" exact="hepatitis" post="B. ALT (WMD=-31.44; 95% CI [-48.57,-14.32]), AST (WMD ="/>
 <result pre="4. Meta-Analysis Forest Plots for Effects In patients with chronic" exact="hepatitis" post="B infection treated with the combination of two liver"/>
 <result pre="on the recovery rate of liver indicators in patients with" exact="hepatitis" post="B; 173 subjects who used a combination of two"/>
 <result pre="Normalization Rates of ALT and TBIL In patients with chronic" exact="hepatitis" post="B infection treated with two vs. one hepatoprotective agent."/>
 <result pre="of ALT, AST and TBIL was conducted, in patients with" exact="hepatitis" post="B (Figure 8). The Funnel plot showed that the"/>
 <result pre="on normalization of ALT, AST and TBIL, in patients with" exact="hepatitis" post="B 7. Discussion The current model is expected to"/>
 <result pre="current model is expected to maximize long-term treatment of severe" exact="liver disease" post="caused by HBV infection to suppress the virus, improve"/>
 <result pre="in drug tolerance due to hepatoprotective agents in patients with" exact="hepatitis" post="B (34, 40). In 2006, Qureshi et al reported"/>
 <result pre="doses of ursodeoxycholic acid reduces ALT levels in patients with" exact="hepatitis" post="B (28). The meta-analysis of the current study showed"/>
 <result pre="ALT, and were a liver function marker in patients with" exact="hepatitis" post="B. The reduction in ALT levels by acetylcysteine was"/>
 <result pre="of serum II-18, IFN-γ and NO in the patients with" exact="hepatitis" post="B. Some studies stated that acetylcysteine should be used,"/>
 <result pre="and that it was more beneficial in early stages of" exact="liver disease" post="(21). The limitations of the study included the retrospective"/>
 <result pre="1LiangGNChenLHGlycyrrhizin injection combined with Danshen injection observe the effect of" exact="hepatitis" post="B liver fibrosis.J Tibetan Med.2010311245 2AlavianSMTabatabaeiSVGhadimiTBeedrapourFKafi-AbadSAGharehbaghianAet al.Seroprevalence of Hepatitis"/>
 <result pre="with other simple noninvasive indices for predicting liver fibrosis and" exact="cirrhosis" post="in hepatitis B virus-infected patients.Liver Int.20103045465310.1111/j.1478-3231.2009.02192.x20074094 6LimYSKimWRThe global impact"/>
 <result pre="simple noninvasive indices for predicting liver fibrosis and cirrhosis in" exact="hepatitis" post="B virus-infected patients.Liver Int.20103045465310.1111/j.1478-3231.2009.02192.x20074094 6LimYSKimWRThe global impact of hepatic"/>
 <result pre="adenosine combine with ursodeoxycholic acid in the treatment of chronic" exact="hepatitis" post="B with severe jaundice.Chin Hosp Pharm J Dis.20033264813 8GaoYSongMZLiangCRClinical"/>
 <result pre="controlled study.BMC Surg.2013133810.1186/1471-2482-13-3824053627 11BobergKMWisloffTKjollesdalKSStovringHKristiansenISCost and health consequences of treatment of" exact="primary biliary cirrhosis" post="with ursodeoxycholic acid.Aliment Pharmacol Ther.201338779480310.1111/apt.1243523915021 12TkaczBDworniakD[Sylimarol in the treatment"/>
 <result pre="Surg.2013133810.1186/1471-2482-13-3824053627 11BobergKMWisloffTKjollesdalKSStovringHKristiansenISCost and health consequences of treatment of primary biliary" exact="cirrhosis" post="with ursodeoxycholic acid.Aliment Pharmacol Ther.201338779480310.1111/apt.1243523915021 12TkaczBDworniakD[Sylimarol in the treatment"/>
 <result pre="silymarin and its combination therapy for the treatment of chronic" exact="hepatitis" post="B.Eur J Clin Microbiol Infect Dis.20133256576910.1007/s10096-012-1789-123247631 14RenBRZhaoYYXuBHWuJLChenJLiangCYResearch of silymarin"/>
 <result pre="Gastroenterol Rep.19991142910980926 19WangNShiXFGuoSHZhangDZRenH[A clinical study of N-acetylcysteine treatment in chronic" exact="hepatitis" post="B patients].Zhonghua Gan Zang Bing Za Zhi.2008167487918647523 20XiaGThe clinical"/>
 <result pre="observation of acetylcysteine injection on 58 cases of chronic severe" exact="hepatitis" post="B.West Chin Med J.2009245123940 21ShiXFGuoSHWuGWangZYRenHLiuQThe clinical curative effect observation"/>
 <result pre="effect observation of acetylcysteine injection on 40 cases of chronic" exact="hepatitis" post="B.J Chongqing Med Univ.200530111521 22ShohratiMDermanakiFBabaeiFAlavianSMEvaluation of the effects of"/>
 <result pre="in paraclinical and oxidative stress parameters of patients with chronic" exact="hepatitis" post="B.Hepat Mon.20101029510022312380 23WuGGuoSHThe Clinic Study of N-Acetylcysteine Injection Therapy"/>
 <result pre="Hepatitis B.Chongqing Med Univer.200432549 24WangXShenSLiNLiY[Effect of Ursodeoxycholi acid on liver" exact="cirrhosis" post="with hepatitis B].Zhong Nan Da Xue Xue Bao Yi"/>
 <result pre="Med Univer.200432549 24WangXShenSLiNLiY[Effect of Ursodeoxycholi acid on liver cirrhosis with" exact="hepatitis" post="B].Zhong Nan Da Xue Xue Bao Yi Xue Ban.2010352171510.3969/j.issn.1672-7347.2010.02.01420197618"/>
 <result pre="methionine combined with ursodeoxycholic acid in the treatment of chronic" exact="hepatitis" post="B with severe jaundice.Chinese J Hos Pharm.20136019 28QureshiHMehdiIAhmedWUAlamSERole of"/>
 <result pre="30FlisiakRProkopowiczDEffect of misoprostol on serum beta2-microglobulin in the course of" exact="viral hepatitis" post="B.Eur J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the"/>
 <result pre="of misoprostol on serum beta2-microglobulin in the course of viral" exact="hepatitis" post="B.Eur J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the"/>
 <result pre="J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the course of" exact="viral hepatitis" post="B.Hepatogastroenterology.199744171419259356866 32GuXBYangXJHuaZLuZHZhangBZhuYFet al.Effect of oxymatrine on specific cytotoxic T"/>
 <result pre="Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the course of viral" exact="hepatitis" post="B.Hepatogastroenterology.199744171419259356866 32GuXBYangXJHuaZLuZHZhangBZhuYFet al.Effect of oxymatrine on specific cytotoxic T"/>
 <result pre="lymphocyte surface programmed death receptor-1 expression in patients with chronic" exact="hepatitis" post="B.Chin Med J (Engl).201212581434822613649 33BaoFYXieJSilybin phospholipid complex combinated with"/>
 <result pre="Med J (Engl).201212581434822613649 33BaoFYXieJSilybin phospholipid complex combinated with interferon treating" exact="hepatitis" post="B.J Cent Plains Med.20063315701 34BaoFYQiuPYAnalyzing the adjunctive therapy of"/>
 <result pre="34BaoFYQiuPYAnalyzing the adjunctive therapy of silibinin phospholipid complex treat chronic" exact="hepatitis" post="B in 86 cases.Shandong Med.2006262631 35KimMYChoMYBaikSKJeongPHSukKTJangYOet al.Beneficial effects of"/>
 <result pre="Capsule combined lamivudine on hepatic fibrosis in patients with chronic" exact="hepatitis" post="B].Zhongguo Zhong Xi Yi Jie He Za Zhi.200626119788017186724 37WuYYaoDKZhuL[Clinical"/>
 <result pre="Oxymatrine combined therapy on liver function in patients with chronic" exact="hepatitis" post="B and liver fibrosis.Pract Clin Med.2014152213 39ZhouXYGaoCGaoXCLiuXLLiLHWangXClinical effects of"/>
 <result pre="effect of interferon α-2b combined with silymarin to treat chronic" exact="hepatitis" post="B.Clin Hepatol.20045302"/>
</results>
